Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21590387 | 0.87 | CYP1A2 (0.36) | CYP1A2GPR119MEN1GAAMAPK1 | |
| SCHEMBL2567549 | 0.80 | TNKS2 (0.35) | NOS2MEN1GAAMAPK1KMT2A | |
| SCHEMBL1051410 | 0.79 | KCNH2 (0.33) | CYP1A2NOS2MEN1KMT2ANOS3 | |
| SCHEMBL1425084 | 0.79 | HTT (0.35) | CYP1A2GPR119MEN1GAAMAPK1 | |
| SCHEMBL29383530 | 0.79 | HTT (0.35) | CYP1A2GPR119MEN1GAAMAPK1 | |
| SCHEMBL21581985 | 0.74 | MAPT (0.38) | CYP1A2MEN1GAAKMT2AHTT | |
| SCHEMBL5562820 | 0.72 | NOS3 (0.42) | CYP1A2NOS2GAANOS3HTT | |
| SCHEMBL21581991 | 0.71 | ALDH1A1 (0.39) | MEN1GAAKMT2AALDH1A1 | |
| SCHEMBL24227834 | 0.71 | ADORA2A (0.34) | GAAMAPK1HTT | |
| SCHEMBL30552533 | 0.71 | ADORA2A (0.34) | GAAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1764099-A2 | Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764098-A1 | Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | CTSD, FURIN, CTSL | CYP1A2 3657/4885GPR119 1059/4885NOS2 3869/4885 |
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | CTSD, CTSL, CTSC | CYP1A2 2259/4885GPR119 811/4885NOS2 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.